Tuesday, November 15, 2016 7:02:38 AM
(note this contains verification that dosing was be 3 pills (3- 100mg/40/mg pills)
SURVEYOR-II, PART 3: EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR (ABT-493/ABT-530) IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 3 INFECTION WITH PRIOR TREATMENT EXPERIENCE AND/OR CIRRHOSIS
http://www.natap.org/2016/AASLD/AASLD_20.htm
compare to Gilead's G-3 Epclusa data
High Efficacy of Sofosbuvir/Velpatasvir In HCV Genotypes 1-6 Infected Patients With Cirrhosis: Pooled Data From the ASTRAL 1, 2 and 3 Trials
http://natap.org/2015/hepDART/hepDART_09.htm
It is a little complicated (or daring leap) since I don't know how each defined treatment experience and what percentage was interferon based versus DAA experienced and differing types of exposures and resultant RAVs
Per this link you can see about past mid point is the table
"SVR by Treatment History in Patients with Cirrhosis"
which shows that Sof/Vel in G-3 resulted in cure rates of;
93% in treatment naive patients w/ cirrhosis (40/43)
89% in treatment experienced patients w/ cirrhosis (33/37)
==================
Compare to Abbvies G/P 2nd gen from above link;
http://www.natap.org/2016/AASLD/AASLD_20.htm
Phase 2 data ("Background and objectives table")
100% SVR in TX naive patients w/ cirrhosis. 12 wk (24/24)
92% SVR in TX experienced patients w/ cirrhosis 12 wk (22/24)
Surveyor part 3
98% SVR in 12 wk tx naive patients w/ cirrhosis (39/40)
91% SVR in 12 wk treatment naive patients w/ cirrhosis (20/22)
96% 16 week treatment experienced w/o cirrhosis (21/22)
96% 16 week treatment experienced with cirrhosis (45/47)
For me Abbvie data looks very competitive..... superior in G-3 to Gilead's
Adding 4 more to treat the hardest to treat group doesn't seem to be excessive for a 16 week total.
I still admit it would be good to see definitions and percentages of treatment experienced since it will make a great difference to results. This seems to be what I could find, however.
This kind of comparison is important since these are the two front line programs Gilead's Epclusa vrs Abbvies G/P 2nd gen.
In the United states this is where the majority of business should be; in G1 primarily, but also in G-3 since it is a previously harder to treat genotype and prior to Epclusa very very expensive, and with some warehousing of patients. (in USA and world wide)
Recent ENTA News
- Enanta Pharmaceuticals to Participate in Investor Conferences in September • Business Wire • 09/03/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 09:24:47 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 08:00:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 08:05:10 PM
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter • Business Wire • 08/05/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 09:29:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 09:30:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 12:38:39 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/17/2024 08:15:05 PM
- Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference • Business Wire • 05/29/2024 11:00:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/08/2024 08:37:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:00:34 PM
- Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference • Business Wire • 05/07/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 08:05:14 PM
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET • Business Wire • 05/06/2024 08:01:00 PM
- Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/30/2024 11:10:00 AM
- Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer • Business Wire • 04/30/2024 11:00:00 AM
- Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024 • Business Wire • 04/29/2024 11:00:00 AM
- Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024 • Business Wire • 04/17/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:27:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:23:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:19:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:15:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:12:41 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM